A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials

Gut

Volumn 53, Issue SUPPL. 4, 2004, Pages

  Sharma, N ^b   Donnellan, C ^c   Preston, C ^c   Delaney, B ^d   Duckett, G ^b   Moayyedi, P ^a,b,d  

^a MCMASTER UNIVERSITY   (Canada)

^b CITY HOSPITAL   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROKINETIC AGENT; PROTON PUMP INHIBITOR; SUCRALFATE;

CLINICAL TRIAL; COCHRANE LIBRARY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG INDUSTRY; DYSPHAGIA; EMBASE; EPIGASTRIC PAIN; ESOPHAGITIS; EVALUATION; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MEDLINE; METHODOLOGY; NAUSEA; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REFLUX ESOPHAGITIS; RELAPSE; REVIEW; SYMPTOMATOLOGY; VISUAL ANALOG SCALE; VOMITING;

CLINICAL TRIALS; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMANS; QUALITY OF LIFE; RECURRENCE; TREATMENT OUTCOME;

EID: 2342467372     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.034371     Document Type: Review

References (149)

1. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996;111:85-92.
2. Armstrong D. Endoscopic evaluation of gastro-esophageal reflux disease. Yale J Biol Med 1999;72:93-100.
3. Donnellan C, Preston C, Moayyedi P. Medical treatments for the short term management of reflux oesophagitis (protocol for a Cochrane review). In: The Cochrane Library, Issue 3. Oxford: Update Software, 2002.
4. Preston C, Donnellan C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease (protocol for a Cochrane review). In: The Cochrane Library, Issue 3. Oxford: Update Software, 2002.
5. Sharp SJ, Thompson SG, Altman DG. The relation between treatment benefit and underlying risk in meta-analysis. BMJ 1996;313:735-8.
6. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisopride. Aliment Pharmacol Ther 1997;11:765-73.
7. Johnson NJ, Boyd EJS, Mills JG, et al. Acute treatment of reflux oesophagitis: a multi-centre trial to compare 150 mg ranitidine bd with 300 mg ranitidine qds. Aliment Pharmacol Ther 1989;3:259-66.
8. Sherbaniuk R, Wensel R, Bailey R, et al. Ranitidine in the treatment of symptomatic gastroesophageal reflux disease. J Clin Gastroenterol 1984;6:9-15.
9. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 mg once daily, omeprazole 20 mg once daily, or ranitidine 150 mg twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-73.
10. Halvorsen L, Lee FI, Wesdorp ICE, et al. Acute treatment of reflux oesophagitis: a multi-centre study to compare 150 mg ranitidine twice daily with 300 mg ranitidine at bedtime. Aliment Pharmacol Ther 1989;3:171-81.
11. Lehtola J, Niemelä S, Martikainen J, et al. Ranitidine, 150 mg three times a day, in the treatment of reflux oesophagitis. A placebo-controlled, double-blind study. Scand J Gastroenterol 1986;21:175-80.
12. Zeitoun P, Desjars de Keranroué N, et al. Omeprazole versus ranitidine in erosive oesophagitis. Lancet 1987;2:621-2.
13. Farup PG, Weberg R, Berstad A, et al. Low-dose antacids versus 400 mg cimetidine twice daily for reflux oesophagitis: a comparative, placebo-controlled, multicentre study. Scand J Gastroenterol 1990;25:315-20.
14. Dobrilla G, Chilovi F, Tafner G, et al. Treatment of erosive reflux oesophagitis: a double-blind multicentre trial with nizatidine 300 mg b.i.d versus placebo. Ital J Gastroenterol 1992;24:338-41.
15. Galmiche JP, Brandstätter G, Evreux M, et al. Combined therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind controlled trial. Gut 1988;29:675-81.
16. Herrera JL, Shoy SS, McCabe M, et al. Sucralfate used as adjunctive therapy in patients with severe erosive peptic esophagitis resulting from gastroesophageal reflux. Am J Gastroenterol 1990;85:1335-8.
17. Maleev A, Mendizova A, Popav P, et al. Cisopride and cimetidine in the treatment of erosive esophagitis. Hepatogastroenterology 1990;37:403-7.
18. Festen HPM, Driessen WMM, Lamers CBH, et al. Cimetidine in the treatment of severe ulcerative reflux oesophagitis; results of an 8-week double-blind study and of subsequent long-term maintenance. Neth J Gastroenterol 1980;23:237-40.
19. Archambault A, Farley A, Cleator IG, et al. Cimetidine therapy for gastroesophageal reflux disease. West J Med 1985;143:616-21.
20. Janisch HD, Hüttemann W, Bauzo MH. Cisapride versus ranitidine in the treatment of reflux esophagitis. Hepatogastroenterology 1988;35:125-7.
21. Festen HPM, Schenk E, Tan G, et al. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. Am J Gastroenterol 1999;94:931-5.
22. McKenna CJ, Mills JG, Goodwin C, et al. Combination of ranitidine and cisapride in the treatment of reflux oesophagitis. Eur J Gastroenterol Hepatol 1995;7:817-22.
23. Bianchi Porro G, Pace F, Songaletti O, et al. Double-blind clinical study of an alginate compound vs ranitidine in patients with gastroesophageal reflux disease. Adv Ther 1992;9:166-73.
24. Petite JP, Aucomte A, Barbare JC, et al. Lansoprazole versus ranitidine dans la traitement d l'oesophagite peptique par reflux. Etude multicentrique. Med Chir Dig 1991;20:462-7:
25. Green JRB, Tildesley G, Theodossi A, et al. Omeprazole 20 mg to 40 mg once daily is more effective in providing complete symptom relief and endoscopic healing in patients with reflux oesophagitis. Br J Clin Res 1995;6:63-76.
26. Uleri S, Squassante L, Castelli G. Ranitidine in the treatment of mild to moderate esophageal reflux: a multicentre trial. Curr Ther Res Clin Exp 1993;53:513-20.
27. Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Scand J Gastroenterol 1993;28:224-8.
28. Breen KJ, Desmond PV, Whelan G. Treatment of reflux oesophagitis: a randomised, controlled evaluation of Cimetidine. Med J Aust 1983;2:555-8.
29. Wesdorp ICE, Dekker W, Festen HPM. Efficacy of fomotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis. Dig Dis Sci 1993;38:2287-93.
30. McCarty-Dawson D, Sue SO, Morrill B, et al. Ranitidine versus Cimetidine in the healing of erosive esophagitis. Clin Ther 1996;18:1150-8.
31. Chopra BK, Kazal HL, Mittal PK, et al. A comparison of the clinical efficacy of ranitidine and sucralfate in reflux esophagitis. J Assoc Physicians India 1992;40:439-41.
32. Vantrappen G, Rutgeerts L, Schurmans P, et al. Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci 1988;33:523-9.
33. The Italian Reflux Oesophagitis Study Group. Omeprazole produces significantly greater healing of erosive or ulcerative reflux oesophagitis than ranitidine. Eur J Gastroenterol Hepatol 1991;3:511-17.
34. Silver MT, Murdock RH, Morrill BB, et al. Ranitidine 300 mg twice daily and 150 four times daily are effective in healing erosive oesophagitis. Aliment Pharmacol Ther 1996;10:373-80.
35. Farley A, Wruble LD, Humphries TJ. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomised clinical trial. Am J Gastroenterol 2000;95:1894-9.
36. Bate CM, Green JRB, Axon ATR, et al. Omeprazole is more effective than Cimetidine for the relief or all grades of gastroesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther 1997;11:755-63.
37. Brown P. Cimetidine in the treatment of reflux oesophagitis. Med J Aust 1979;2:96-7.
38. Dekkers CPM, Beker JA, Thjodleifsson B, et al. The European Rabeprazole Study Group. Double-blind comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999;11:49-57.
39. Evreux M. Sucralfate versus alginate/antacid in the treatment of peptic esophagitis. Am J Med 1987;83(Suppl 3B):48-50.
40. Van Rensburg CJ, Honiboll PJ, Grundling H de K, et al. Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. Aliment Pharmacol Ther 1996;10:397-401.
41. Klinkenberg-Knol EC, Jansen JMBJ, Festen HPM, et al. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1987;1:349-51.
42. Richter JE, Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomised clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 2000;95:3071-80.
43. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomised controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000;14:1249-58.
44. Van Zyl JH, Grundling H de K, van Rensburg G, et al. Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux oesophagitis: a randomised, double-blind, parallel and multicentre study. Eur J Gastroenterol Hepatol 2000;12:197-202.
45. Jonsen JBMJ, Van Oene JC, the Dutch Lansoprazole Study Group. Standard-dose lonsoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. Aliment Pharmacol Ther 1999;13:1611-20.
46. Mulder CJ, Dekker W, Gerretson M, on behalf of the Dutch Lansoprazole Study Group. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IV a (a Dutch multicentre trial). Eur J Gastroenterol Hepatol 1996;8:1101-6.
47. Dehn TCB, Shepherd HA, Colin-Jones D, et al. Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of systematic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 hour pH monitoring. Gut 1990;31:509-13.
48. Armbrecht U, Abucar A, Hameeteman W, et al. Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole - comparison of 24-hour intragastric and oesophageal pH. Aliment Pharmacol Ther 1997;11:959-65.
49. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomised controlled trial. Am J Gastroenterol 2001;96:656-65.
50. Sontag SJ, Hirschowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the US multicentre study. Gastroenterology 1992;102:109-18.
51. Simon TJ, Berlin RG, Tipping R, et al. Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Scand J Gastroenterol 1993;28:375-80.
52. Robinson M, Decktor DL, Maton PN, et al. Omeprazole is superior to ranitidine plus metaclopramide in the short-term treatment of erosive esophagitis. Aliment Pharmacol Ther 1993;7:67-73.
53. Bardhan KD, Hawkey G, Long RG, et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. Aliment Pharmacol Ther 1995;9:145-51.
54. Vcev A, Stimac D, Vceva A, et al. Pantoprazole versus omeprazole in the treatment of reflux esophagitis. Acta Med Croatico 1999;53:79-82.
55. Wesdorp E, Bartelsman J, Pape K, et al. Oral Cimetidine in reflux esophagitis: a double blind controlled trial. Gastroenterology 1978;74:821-3.
56. Mee AS, Rowley JL. Rapid symptom relief in reflux oesophagitis: a comparison of lanzoprazole and omeprazole. Aliment Pharmacol Ther 1996;10:757-63.
57. Geldof H, Hazelhoff B, Otten MH. Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a double-blind comparison with ranitidine. Aliment Pharmacol Ther 1993;7:409-15.
58. Goy J, Maynard JH, McNaughton WM, et al. Ranitidine and placebo in the treatment of reflux oesophagitis: a double-blind randomised trial. Med J Aust 1983;2:558-61.
59. Blum AL, Riecken EO, Dammann HG, et al. Comparison of Omeprazole and ranitidine in the treatment of reflux oesophagitis. N Engl J Med 1986;314:716.
60. Bremner CG, Marks IN, Segal I, et al. Reflux esophagitis therapy: sucralfate versus ranitidine in a double blind multicenter trial. Am J Med 1991;91(Suppl 2A):119S-21S.
61. Carling L, Cronstedt J, Engqvist A, et al. Sucralfate versus placebo in reflux esophagitis: a double-blind, multicentre study. Scand J Gastroenterol 1988;23:1117-24.
62. Di Mario F, Battaglia G, Ferrana M, et al. Sucralfate gel versus ranitidine in the treatment of gastroesophageal reflux disease: a controlled study. Curr Ther Res Clin Exp 1994;55:303-9.
63. Ros E, Toledo-Pimentel V, Bardas JH, et al. Healing of erosive esophagitis with sucralfate and cimetidine: influence of pretreatment lower esophageal sphincter pressure and serum pepsinogen I levels. Am J Med 1991;91:2A:107S-13S.
64. Mössner J, Hölscher AH, Herz R, et al. A double-blind study of pantoprazole and ameprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995;9:321-6.
65. Corinaldesi A, Valentini M, Belaïche J, et al. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Aliment Pharmacol Ther 1995;9:667-71.
66. Palmer RH, Miller DM, Hedrich DA, et al. Cimetedine QID and BID in rapid heartburn relief and healing of lesions in gastroesophageal reflux disease. Clin Ther 1993;15:994-1001.
67. Mekel RCPM. An international multicentre collaborative trail comparing Cimetidine 800 mg twice daily and 400 mg four times daily in the treatment of reflux esophagitis. Curr Ther Res Clin Exp 1988;44:646-57.
68. Bovero E, Cheli R, Barbara L, et al. Short-term treatment of reflux oesophagitis with ranitidine 300 mg nocte: Italian multicentre study. Hepatogastroenterology 1987;34:155-9.
69. Masci E, Testoni PA, Passaretti S, et al. Comparison of ranitidine, domperidone maleate and ranitidine+domperidone maleate in the short-term treatment of reflux oesophagitis. Drugs Exp Clin Res 1985;10:687-92.
70. Guslandi M, Testoni PA, Possaretti S, et al. Ranitidine versus metaclopramide in the medical treatment of reflux esophagitis. Hepatogastroenterology 1983;30:96-8.
71. Koop H, Scepp W, Dammann HG, et al. Comparative trial of pantoprazole and ranitidine in the treatment of reflux oesophagitis. J Clin Gastroenterol 1995;20:192-5.
72. Hameeteman W, Boomgaord MVD, Dekker W, et al. Sucralfate versus cimetidine in reflux esophagitis. J Clin Gastroenterol 1987;9:390-4.
73. Arvanitakis C, Nikopoulis A, Theaharidis A, et al. Cisopride and ranitidine in the treatment of gastro-oesophageal reflux disease - a comparative randomised double-blind trial. Aliment Pharmacol Ther 1993;7:635-41.
74. Earnest DI, Dorsch E, Jones J, et al. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux oesophagitis. Am J Gastroenterol 1998;93:238-43.
75. Grove O, Bekker C, Jeppe-Hansen MG, et al. Ranitidine and high-dose antacid in reflux cesophagitis. Scand J Gastroenterol 1985;20:457-61.
76. Richter JE, Long JF. Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study. Am J Gastroenterol 1995;90:423-30.
77. Anand BS, Balakrishnan V, Desai D, et al. Controlled comparison of ranitidine and cimetidine in patients of duodenal ulcer, gastric ulcer and reflux oesophagitis: a multicentre study. Indian J Gastroenterol 1986;5:29-33.
78. Beretta L, Bortoli A, de Barolo G, et al. Nizotidine (450 mg/day) versus ranitidine (450 mg/day) in the treatment of erosive esophagitis: a multicentre clinical trial. Curr Ther Res Clin Exp 1991;49:968-73.
79. Williams RM, Orlando RC, Bozymski EM, et al. Multicentre trial of sucralfate suspension for the treatment of reflux esophagitis. Am J Med 1987;83:61-5.
80. Temple JG, Bradby GVH, O'Connor F, et al. Cimetidine and metaclopramide in gastroesophageal reflux disease. BMJ 1983;286:1863-4.
81. Johansson K-E, Boeryd B, Johansson J, et al. Double-blind crossover study of ranitidine and placebo in gastroesophageal reflux disease. Scand J Gastroenterol 1986;21:769-78.
82. Robertson CS, Evans DF, Ledingham SJ, et al. Cisapride in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993;7:181-90.
83. Palmer RH, Frank WO, Rockhold FW, et al. Cimetidine 800 mg twice daily for healing erosions and ulcers in gastroesophageal reflux disease. J Clin Gastroenterol 1990;12(Suppl 2):S29-34.
84. Nelis G. Ranitidine in the management of gastroesophageal reflux disease. Neth J Med 1985;28:197-200.
85. Sontag SJ, Robinson M, McCallum RW, et al. Ranitidine therapy for gastroesophageal reflux disease: results of a large double-trial. Arch Intern Med 1987;147:1485-91.
86. Robinson M, Sahba B, Avner D, et al. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther 1995;9:25-31.
87. Delchier JC, Cohen G, Humphries TJ. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastroesophageal reflux disease. Scand J Gastroenterol 2000;33:1245-50.
88. Sabesin SM, Berlin RG, Humphries TJ, et al. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. USA Merck Gastroesophageal Reflux Study Group. Arch Intern Med 1991;151:2394-400.
89. Dettmer A, Vogt R, Sielaff F, et al. Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild oesophagitis. Aliment Pharmacol Ther 1998;12:865-72.
90. Hine KR, Holmes GKT, Melikion V, et al. Ranitidine in reflux oesophagitis: a double-blind placebo-controlled study. Digestion 1987;29:119-23.
91. Vermijden JR, Tytgat DNJ, Schotborgh RH, et al. Combination therapy of sucralfate and ranitidine compared with sucralfate monotherapy in patients with peptic reflux disease. Scand J Gastroenterol 1992;27:81-4.
92. Fielding JF, Doyle GD. Comparison between ranitidine and cimetidine in the treatment of reflux oesophagitis. Ir Med J 1984;77:356-7.
93. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-12.
94. Kar P, Gurtoo A, Jain SK, et al. Ranitidine versus placebo: a double-blind trial in the management of reflux oesophagitis. Curr Ther Res Clin Exp 1990;47:731-4.
95. Elsborg L, Jørgensen F. Sucralfate versus cimetidine in reflux oesophagitis. Scand Gastroenterol 1991;26:146-50.
96. Laitinen S, Ståhlberg M, Kairalouma MI, et al. Sucralfate and alginate/antacid in reflux esophagitis. Scand J Gastroenterol 1985;20:229-32.
97. Dakkak M, Jones BP, Scott MGB, et al. Comparing the efficacy of cisopride and ranitidine in oesophagitis: a double-blind, parallel group study in general practice. Br J Clin Pract 1994;48:10-14.
98. Dent J, Hetzel DJ, Mackinnon MA, et al. Evaluation of omeprazole in reflux oesophagitis. Scand J Gastroenterol Suppl 1989;166:76-82.
99. Simon B, Mueller P. Comparison of the effect of sucralfate and ranitidine in reflux esophagitis. Am J Med 1987;83:43-7.
100. Baldi F, Bianchi Parro G, Dobrilla G, et al. Cisapride versus placebo in reflux esophagitis: a multicentre double-blind trial. J Clin Gastroenterol 1988;10:614-18.
101. Sandmark S, Carlsson R, Fausa O, et al. Omeprazole or ranitidine in the treatment of reflux oesophagitis: results of a double-blind, randomised, Scandinavian multicentre study. Scand J Gastroenterol 1988;23:625-32.
102. Havelund T, Laursen LS, Skoubo-Kristnesen E, et al. Omeprazole and ranitidine in the treatment of reflux oesophagitis - a double-blind comparative trial. BMJ 1988;296:89-91.
103. Powell-Jackson P, Barkley M, Northfield TC. Effect of cimetidine in symptomatic gastroesophageal reflux. Lancet 1978;2:1068-9.
104. Petite JP, and the Group Multicentrique. Efficacité comparée du lansoprazole et de l'oméprazole dans le traitement delœsophagite peptique. Med Chir Dig 1995;24:291-3.
105. Simon TJ, Berenson MM, Berlin RG, et al. Randomized, placebo-controlled comparison of fomotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis. Aliment Pharmacol Ther 1994;8:71-9.
106. Pace F, Sangaletti O, Bionchi Porra G. Short and long-term effect of two different dosages of ranitidine in the therapy of reflux oesophagitis. Ital J Gastroenterol 1990;22:28-32.
107. Toussaint J, Gossuin A, Deruyterre M, et al. Healing and prevention of relapse of reflux oesophagitis by cisapride. Gut 1991;32:1280-5.
108. Gustavsson S, Bergström R, Erwall C, et al. Reflux esophagitis: Assessment of therapy effects and observer variation by video documentation of endoscopy findings. Scand J Gastroenterol 1987;22:585-91.
109. Noritsugu U, Miki K, Hoshino E. Lansoprazole versus fomotidine in symptomatic reflux oesophagitis: a randomised multicentre study. J Clin Gastroenterol 1995;20:S17-23.
110. Euler AR, Murdock RH, Wilson TH, et al. Ranitidine is effective therapy for erosive esophagitis. Am J Gastroenterol 1993;88:520-4
111. Venables CW, Dell D, Eccleston D. A double-blind study of metaclopramide in symptomatic peptic oesophagitis. Postgrad Med J 1973;49(Suppl 4):73-6
112. Quik RF, Cooper MJ, Gleeson M, et al. A comparison of two doses of nizotidine versus placebo in the treatment of reflux oesophagitis. Aliment Pharmacol Ther 1990;4:201-11.
113. Kaul B, Peterson H, Erichsen H, et al. Gastroesophageal reflux disease: acute and maintenance treatments with cimetidine. Scand J Gastroenterol 1986;21:139-45.
114. Hatlebakk JG, Johnsson F, Vilien M, et al. The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease. Scand J Gastroenterol 1997;32:1100-6.
115. Bate CM, Booth SN, Crowe JP, et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group. Gut 1995;36:492-8.
116. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux oesophagitis. N Engl J Med 1995;33:1106-10.
117. Blum AL, Adami B, Bouzo MH, et al. Effect of cisapride on relapse of esophagitis. A multinational, placebo-controlled trial in patients healed with an antisecretory drug. The Italian Eurocis Trialists. Dig Dis Sci 1993;38:551-60.
118. Hatlebakk JG, Berstod A. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther 1997;11:365-72.
119. Houcke P, Goldfoin D, Guyot P, et al. Prévention des récidives de l'œsophagite par reflux par le lansoprazole: 30 mg un jour sur deux ou 15 mg tous les jours? Acta Endoscopica 2000;30:243-53.
120. Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomised, double-blind, placebo controlled study of efficacy and safety. Aliment Pharmacol Ther 2001;15:927-35.
121. Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996;10:529-39.
122. Staerk Laursen L, Havelund T, Bondesen S, et al. Omeprazole in the long-term treatment of gastroesophageal reflux disease: a double-blind randomised dose-finding study. Scand J Gastroenterol 1995;30:839-46.
123. Carling L, Axelsson CK, Forssell H, et al. Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study. Aliment Pharmacol Ther 1998;12:985-90.
124. Sontag SJ, Kagut DG, Fleischmann R, et al. Lansoprazole prevents recurrence of erosive reflux disease previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group. Am J Gastroenterol 1996;91:1758-65.
125. Sontag SJ, Robinson M, Roufoil W, et al. Daily ameprazole surpasses intermittent dosing in preventing relapse of oesophagitis: a US multi-centre double-blind study. Aliment Pharmacol Ther 1997;11:373-90.
126. Hallerbäck B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux oesophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology 1994;107:1305-11.
127. Escourrou J, Deprez P, Saggiora A, et al. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis. Aliment Pharmacol Ther 1999;13:1481-91.
128. Plein K, Hotz J, Wurzer H, et al. Pantoprazole 20 mg is an effective maintenace therapy for patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2000;12:425-32.
129. Siman TJ, Roberts WG, Berlin RG, et al. Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitis. Clin Ther 1995;17:1147-56.
130. Thjodliefsson B, Beker JA, Dekkers C, et al. Rabeprazole vs omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease. Dig Dis Sci 2000;45:845-53.
131. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management if patients with heartburn without oesophagitis - a placebo-controlled randomised trial. Aliment Pharmacol Ther 1999;13:907-14.
132. Venables TL, Newland RD, Patel AC, et al. Maintenance treatment for gastro-esophageal reflux disease: a placebo-controlled evaluation of 10 mg omeprazole once daily in general practice. Scand J Gastroenterol 1997;32:627-32.
133. Lundell L, Backman L, Ekström P, et al. Prevention of relapse of reflux oesophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol 1991;26:246-56.
134. Johnson Dam Benjamin SB, Vakil NB, Goldstein JL, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomised, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001;91:27-34.
135. Bardhan KD, Cherian P, Voishnavi A, et al. Erosive esophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo. Gut 1998;43:458-64.
136. Lauritsen K, Deviere J, Bigard MA, et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropale study results. Aliment Pharmacol Ther 2003;17:333-41.
137. Birbara C, Breiter J, Perdomo C, et al. for the Rabeprazole Study Group. Rabeprazole for the prevention of recurrent erosive or ulcerative gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 2000;12:889-97.
138. Tytgat GNJ, Koelz H-R, Vosmaer GDC, et al. Sucralfate maintenance therapy in reflux oesophagitis. Am J Gastroenterol 1995;90:1233-7.
139. Kimmig JM. Treatment and prevention of relapse of mild oesophagitis with omeprazole and cisapride: comparison of two strategies. Aliment Pharmacol Ther 1995;9:281-6.
140. Tytgat GNJ, Anker Hansen OJ, Carling L, et al. Effect of cisopride on relapse of reflux oesophagitis, healed with an antisecretory drug. Scand J Gastroenterol 1992;27:175-83.
141. Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994;35:590-8.
142. Dent J. Australian Clinical Trials of omeprazole in the management of reflux oesophagitis. Digestion 1990;47:69-71.
143. Caos A, Maskovitz M, Dayal Y, et al. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. The Rabeprazole Study Group. Am J Gastroenterol 2000;95:3081-8.
144. MacDougall NI, Watson RGP, Collins JSA, et al. Maintenance therapy with cisapride after healing of erosive oesophagitis: a double-blind placebo-controlled trial. Aliment Pharmacol Ther 1997;11:487-95.
145. Angelini G, Castagnini A, Sgarbi D, et al. Confronto tra omeprazalo e ranitidina nel trattamento a medio termine dell'esofagite peptica. Studio multicentre, praspettico, randomizzato. G Ital End Dig 1993;16:85-9.
146. Piantadosi S, Byar DP, Green SB. The ecological fallacy. Am J Epidemiol 1988;127:893-904.
147. McCall E. Best practice in symptom assessment: a review. Gut 2004;53(Suppl IV):iv49-54.
148. Wyrwich KW, Staebler Tardito VM. A blueprint for symptom scales and responses: measurement and reporting. Gut 2004;53(Suppl IV):iv45-8.
149. Watson RG, Thom TC, Johnston BT, et al. Double blind crossover placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - the "sensitive oesophagus". Gut 1997;40:587-90.